7 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
LY4268989 in Adults With Moderately to Severely Active Ulcerative ColitisDigestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitisRecruitingPhase 22026-10-08NCT07415044
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver diseaseRecruitingPhase 32026-10-08NCT07165028
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightBody Weight, Crohn disease, Digestive System Diseases, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, nutritional disorder, obesity disorder, overnutritionRecruitingPhase 32026-10-07NCT06937099
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyBody Weight, Digestive System Diseases, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, nutritional disorder, obesity disorder, overnutrition, ulcerative colitisRecruitingPhase 32026-10-07NCT06937086
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's DiseaseCrohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorderActive, not recruitingPhase 32026-08-11NCT04232553
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitisActive, not recruitingPhase 32026-04-20NCT03519945
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased RiskBlood-Borne Infections, DNA Virus Infections, Digestive System Diseases, Digestive System Neoplasms, Fibrosis, Hepadnaviridae infectious disease, Infections, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, carcinoma, cirrhosis of liver, epithelial neoplasm, hepatitis, hepatitis B virus infection, hepatocellular carcinoma, infectious disease, liver cancer, liver disorder, neoplasm, viral hepatitis, viral infectious diseaseActive, not recruitingNot stated2025-10-15NCT05064553